Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9GZQ3
UPID:
COMD5_HUMAN
Alternative names:
Hypertension-related calcium-regulated gene protein
Alternative UPACC:
Q9GZQ3; D3DWN7; Q9NVN6; Q9UHX5
Background:
COMM domain-containing protein 5, also known as the Hypertension-related calcium-regulated gene protein, plays a crucial role in cellular processes. It modulates the activity of cullin-RING E3 ubiquitin ligase complexes, regulates cell proliferation, and influences the cell cycle's G2/M phase transition through p21/CDKN1A transactivation via a p53/TP53-independent pathway. Additionally, it is involved in kidney proximal tubule morphogenesis and down-regulates NF-kappa-B activation.
Therapeutic significance:
Understanding the role of COMM domain-containing protein 5 could open doors to potential therapeutic strategies.